GenMark Diagnostics (GNMK) Reports In-Line Q4 EPS

GenMark Diagnostics (NASDAQ: GNMK) reported Q4 EPS of ($0.27), in-line with the analyst estimate of ($0.27). Revenue for the quarter came in at $14.9 million versus the consensus estimate of $14.83 million.

For earnings history and earnings-related data on GenMark Diagnostics (GNMK) click here.

You May Also Be Interested In

• Rivian reports record Q3 deliveries, beats estimates, shares rise
• First Watch (FWRG) PT Lowered to $15 at DA Davidson, Buy Rating Maintained
• McCormick & Co. (MKC) Tops Q3 EPS by 10c, Beats on Revenue; Offers EPS Guidance